###begin article-title 0
PPARalpha Deficiency in Inflammatory Cells Suppresses Tumor Growth
###end article-title 0
###begin p 1
Conceived and designed the experiments: SH DP AK. Performed the experiments: SH DP AK. Analyzed the data: SH DP AK. Contributed reagents/materials/analysis tools: SH. Wrote the paper: SH DP AK. Other: Participated in designing the studies and data analysis and participated in the intellectual input and discussions with AK and DP, and contributed to the writing of the paper: JF. Participated in designing the studies and data analysis and participated in the intellectual input and discussions with AK and DP and contributed to the writing of the paper: SH. Participated in designing all bone marrow transplantation and antibody depletion studies and performed the and contributed to the writing of the paper: GM. Participated in data analysis and the intellectual input and discussions with AK and DP: MK. Participated in designing the corneal assays and performed them: CB. Participated in designing all the metastasis assays and performed them: DB. Participated in designing the bone marrow transplantation experiments and the intellectual input and discussions with GM: RM.
###end p 1
###begin p 2
###xml 652 656 <span type="species:ncbi:10090">mice</span>
Inflammation in the tumor bed can either promote or inhibit tumor growth. Peroxisome proliferator-activated receptor (PPAR)alpha is a central transcriptional suppressor of inflammation, and may therefore modulate tumor growth. Here we show that PPARalpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of the endogenous angiogenesis inhibitor thrombospondin-1 and prevents tumor growth. Bone marrow transplantation and granulocyte depletion show that PPARalpha expressing granulocytes are necessary for tumor growth. Neutralization of thrombospondin-1 restores tumor growth in PPARalpha-deficient mice. These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 218 221 218 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Bhowmick1">[1]</xref>
Non-neoplastic "host" cells, such as endothelial, stromal and inflammatory cells, play a critical role in tumor growth; and genes prognostic for cancer outcome may be expressed in the non-neoplastic tissue compartment [1]. While tumor angiogenesis has been intensely studied for more than two decades and has become an accepted target in cancer therapy, it is only in the last few years that inflammation has entered center stage of investigations into non-cell autonomous processes in cancer.
###end p 4
###begin p 5
###xml 264 267 264 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lin1">[2]</xref>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-deVisser1">[3]</xref>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-deVisser1">[3]</xref>
###xml 416 419 416 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Zhang1">[5]</xref>
###xml 804 807 796 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Pikarsky1">[6]</xref>
Chronic inflammation in the tumor stroma has long been known to contribute to tumor progression. Increased infiltration of innate immune cells to the tumor, such as macrophages, mast cells and neutrophils, correlates with increased angiogenesis and poor prognosis [2], [3]. In contrast, lymphocytic/monocytic inflammatory infiltrates are sometimes associated with tumor inhibition and a more favorable prognosis [3]-[5]. Recently, NF-kappaB, a central positive regulator of inflammation, has emerged as a molecular link between inflammation and cancer growth. NF-kappaB promotes tumor growth not only in a cancer cell-autonomous manner by transactivating anti-apoptotic genes, but it also stimulates inflammatory processes in the microenvironment that lead to the production of tumor-promoting cytokines [6].
###end p 5
###begin p 6
###xml 183 186 175 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Staels1">[7]</xref>
###xml 250 253 238 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Devchand1">[8]</xref>
###xml 376 379 360 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Gonzalez1">[9]</xref>
###xml 580 584 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Peters1">[10]</xref>
###xml 586 590 558 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Hays1">[11]</xref>
###xml 705 709 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Collett1">[12]</xref>
###xml 711 715 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Thuillier1">[13]</xref>
###xml 1063 1067 1023 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Michalik1">[14]</xref>
###xml 1069 1073 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Tordjman1">[15]</xref>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 514 518 <span type="species:ncbi:10090">mice</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
Conversely, PPARalpha, a ligand-activated nuclear receptor/transcription factor, is a key negative regulator of inflammation. Activation of PPARalpha by ligands inhibits inflammation [7] whereas PPARalpha deficient mice exhibit enhanced inflammation [8]. Despite PPARalpha's role in suppressing inflammation, it appears to be necessary and sufficient for rodent tumorigenesis [9]. In fact, prolonged PPARalpha activation by peroxisome proliferators induces hepatocarcinogenesis in rodents; conversely PPARalpha KO mice are resistant to tumorigenesis induced by PPARalpha agonists [10], [11]. This may be due in part to cell-autonomous effect of PPARalpha, because it is expressed in many tumor cell lines [12], [13]. Another possibility is that in PPARalpha deficient mice, stromal processes, such as inflammation, inhibit tumor growth, which results in microscopic-sized tumors that remain dormant. The role of PPARalpha in inflammation has been extensively studied in normal physiological processes (wound healing) and cardiovascular diseases (atherosclerosis) [14], [15]; but the effect of PPARalpha mediated suppression of inflammation on tumors has not been characterized. Here we show that overt inflammation in the absence of PPARalpha in the host tissue prevents tumor growth. This indicates that in contrast to the emerging notion that inflammatory infiltrates promote tumors, the specific nature of the inflammatory process must be considered when linking inflammation to tumorigenesis.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
Deletion of PPARalpha in Host Tissue inhibits Tumor Growth and Metastasis
###end title 8
###begin p 9
###xml 257 261 253 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Serrano1">[16]</xref>
###xml 722 739 698 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figures 1A and 1B</xref>
###xml 1109 1118 1069 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1C</xref>
###xml 16 22 <span type="species:ncbi:10090">murine</span>
###xml 187 192 <span type="species:ncbi:10090">mouse</span>
###xml 226 230 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
We used several murine models to determine how the increased inflammatory response observed in the absence of PPARalpha affects tumor growth and metastasis. Fi rst, we stably transformed mouse embryonic fibroblasts (MEF) with SV40 large T antigen and H-ras [16] to obtain isogeneic tumorigenic cell lines that were either wild type (PPARalpha(+/+)MEF/RS) or lacked PPARalpha (PPARalpha(-/-)MEF/RS). These two tumorigenic cell lines allowed us to distinguish between the tumor cell- autonomous role and the host tissue role of PPARalpha. We found that the growth of these isogeneic tumors derived from both cell lines was almost completely suppressed in KO host mice that lacked PPARalpha, but not in WT animals, p<0.0001 (Figures 1A and 1B). Although tumors derived from MEFs deficient of PPARalpha were partially suppressed in WT animals (by 41%), indicating a cell-autonomous role of PPAR in tumor growth, a drastic effect in tumor suppression was observed when the host was PPARalpha deficient both in the case of PPARalpha(+/+) tumors (87% suppression) as well as PPARalpha(-/-) tumors (97% suppression) (Figure 1C). These results suggest that the presence of PPARalpha gene in the host animals is essential for tumor growth.
###end p 9
###begin p 10
###xml 284 293 276 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1D</xref>
###xml 41 47 <span type="species:ncbi:10090">murine</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
To examine the role of established tumor murine models we first used WT and KO mice derived from WT (S1)xKO (S4) crossmating. The growth of B16-BL6 tumor was almost completely inhibited in the PPARalpha KO (S1/S4) host, but was not affected in PPARalpha WT (S1/S4) animals, p<0.0001 (Figure 1D). This result suggests that presence of the PPARalpha gene in the host tissue is essential to support tumor growth.
###end p 10
###begin p 11
###xml 327 338 315 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1E&#8211;G</xref>
###xml 633 637 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lyden1">[17]</xref>
###xml 639 648 627 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000260.s001">Figure S1</xref>
###xml 820 831 804 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1E&#8211;G</xref>
###xml 1378 1387 1338 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1H</xref>
###xml 1704 1713 1656 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1I</xref>
###xml 175 181 <span type="species:ncbi:10090">murine</span>
###xml 742 746 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
###xml 898 902 <span type="species:ncbi:10090">mice</span>
###xml 1086 1090 <span type="species:ncbi:10090">mice</span>
###xml 1544 1548 <span type="species:ncbi:10090">mice</span>
###xml 1619 1623 <span type="species:ncbi:10090">mice</span>
Given that the above results clearly suggest that the status of the PPARalpha locus in the host affects tumor growth, we next evaluated the growth of three PPARalpha-positive murine tumor models in PPARalpha KO (S4) animals, including Lewis lung carcinoma (LLC), metastatic B16-F10/GFP melanoma, and B16-BL6 melanoma, p<0.001 (Figure 1E-G). LLC tumors have been reported to grow aggressively at similar rates in the Sv129, C57BL/6 and Sv129/C57BL/6 strains without evidence of transplantation immunity. This suggests that disparity in either minor or major immunohistocompatibility genes does not affect tumor growth in these models [17] (Figure S1). Macroscopic growth of LLC and B16-F10/GFP tumors was completely suppressed in PPARalpha KO mice, even when mice were monitored for more than 100 days post implantation (Figure 1E-G). Similarly, tumor metastasis was also suppressed in PPARalpha KO mice. When B16-F10/GFP melanoma cells and engineered PPARalpha deficient tumor cells, PPARalpha (-/-) MEF/RS (see below) were injected via tail vein, 21 out of 21 PPARalpha wild-type (WT) mice died of lung and/or liver metastasis by day 21. In contrast, the PPARalpha KO hosts suppressed metastatic growth in lung and liver, reducing the infiltration of the tumor cells from 50-70% of normal organ tissue area in the WT hosts to less than 10% tissue area in PPARalpha KO animals (Figure 1H). Furthermore, the incidence of metastasis, as measured by the number of histologically identified metastatic foci, was strongly suppressed in PPARalpha KO mice. The majority of microscopic fields of liver sections in PPARalpha KO mice revealed only one or two metastases compared to 4-5 foci in livers of WT hosts (Figure 1I). Together these findings support the importance of PPARalpha expression in host cells for tumor development.
###end p 11
###begin p 12
###xml 250 254 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Achilles1">[18]</xref>
###xml 256 260 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Udagawa1">[19]</xref>
###xml 433 442 421 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g002">Figure 2A</xref>
###xml 531 532 515 516 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 534 543 518 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g002">Figure 2A</xref>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
The non-growing PPARalpha(-/-)MEF/RS tumors in PPARalpha KO mice prompted us to investigate whether these tumors were just a mass of connective tissue or viable dormant microtumors, a state in which tumor cell proliferation is balanced by cell death [18], [19]. Analysis of the small (<2 mm), non-growing lesions at the injection site identified viable PPARalpha(-/-) MEF/RS large T antigen expressing and proliferating tumor cells (Figure 2A). When re-transplanted to PPARalpha WT mice, these tumors grew rapidly to over 10,000 mm3 (Figure 2A) indicating that PPARalpha in the host can rescue PPARalpha -/- tumor cells. Although these findings suggest that the presence of PPARalpha both in the tumor cells as well as in the host is necessary for unabated tumor growth, they also demonstrate that PPARalpha in tumor cells is not necessary for tumor cell viability. Conversely, the results underscore the importance of PPARalpha in the host tissue to sustain tumor growth.
###end p 12
###begin p 13
###xml 173 182 169 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g002">Figure 2B</xref>
###xml 297 306 289 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g002">Figure 2B</xref>
###xml 574 583 562 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g002">Figure 2B</xref>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Histological examination revealed a pronounced leukocyte infiltration (based on CD45-positive staining) in the non-necrotic stroma of all tumors grown in PPARalpha KO mice (Figure 2B). In contrast, PPARalpha WT animals exhibited the usual leukocytic infiltrate that was limited to necrotic areas (Figure 2B). Moreover, PECAM-1 staining performed to visualize blood capillaries revealed a decreased microvessel density in tumors from PPARalpha KO hosts when compared to tumors from WT hosts of the same size at day 7 (data not shown), as well as at day 30 post implantation (Figure 2B). Therefore, the absence of PPARalpha in the stromal tissue of the host appears to have two major consequences: an increase in inflammation and a decrease in tumor angiogenesis.
###end p 13
###begin title 14
Loss of Host PPARalpha Inhibits Corneal Neovascularization and Permeability
###end title 14
###begin p 15
###xml 322 329 314 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 620 624 612 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Chang1">[20]</xref>
###xml 626 630 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Seghezzi1">[21]</xref>
###xml 823 832 811 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g003">Figure 3A</xref>
###xml 1008 1017 996 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g003">Figure 3A</xref>
###xml 1053 1057 1041 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Chang1">[20]</xref>
###xml 1183 1190 1167 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1205 1209 1189 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Miles1">[22]</xref>
###xml 1211 1215 1195 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Dvorak1">[23]</xref>
###xml 1318 1327 1302 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g003">Figure 3B</xref>
###xml 1387 1396 1367 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g003">Figure 3B</xref>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 645 649 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 1241 1245 <span type="species:ncbi:10090">mice</span>
###xml 1381 1385 <span type="species:ncbi:10090">mice</span>
Decreased microvessel density may reflect direct or indirect antiangiogenic effects caused by the lack of PPARalpha activity. Because all tumors used here are known to produce the angiogenic cytokine VEGF, we first investigated whether PPARalpha plays a role in VEGF signaling in the host cells. We employed two different in vivo VEGF-activity assays: VEGF-mediated, FGF2-induced corneal neovascularization, and VEGF-induced vascular permeability. Implantation of pellets containing 20 ng of FGF2 into the corneas of mice promotes the extravasation of leukocytes and stimulates VEGF-dependent corneal neovascularization [20], [21]. PPARalpha KO mice exhibited >50% inhibition of vessel length when compared to WT animals, while the initial sprouting (reflected in clock hours of the neovascularized area) was not affected (Figure 3A). Complete abrogation of angiogenesis in the WT mice in the presence of soluble VEGF-receptor-1 (VEGFR1) confirmed that angiogenesis in these WT animals was mediated by VEGF (Figure 3A), consistent with previous studies [20]. In our second approach, we evaluated whether host PPARalpha affected VEGF-induced vascular permeability, a standard test of in vivo VEGF activity [22], [23]. In response to VEGF, WT mice displayed Evans blue extravasation into the subcutaneous skin and ears (Figure 3B) that was 300-400% greater than that of PPARalpha KO mice (Figure 3B). Together, these results indicate that host PPARalpha is indispensable for VEGF-dependent signaling.
###end p 15
###begin title 16
PPARalpha Deficiency in Bone Marrow Cells Inhibits Tumor Growth
###end title 16
###begin p 17
###xml 453 462 441 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4A</xref>
###xml 623 632 603 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4A</xref>
###xml 799 809 779 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000260.s002">Figure S2A</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
Given the observation that the tumor bed of PPARalpha KO mice exhibited an increased inflammatory response, we performed reciprocal bone marrow transplantations between WT and KO mice to determine whether the hematopoietic compartment of PPARalpha deficient mice plays a role in the inhibition of tumor growth. Bone marrow cells from WT mice were capable of restoring the "wild-type" tumor growth pattern of B16-BL6 tumors in PPARalpha deficient hosts (Figure 4A). Conversely, PPARalpha-deficient bone marrow cells, when transplanted into WT hosts, conferred the tumor-suppressing phenotype of PPARalpha KO mice, p<0.0001 (Figure 4A). It is important to note that in the bone marrow transplantation protocol used, >90% of the hematopoietic system of the recipient was derived from the donor marrow (Figure S2A); this argues against the possibility that PPARalpha KO bone marrow cells have a direct, "dominant-negative" effect that overrides a tumor promoting effect of WT bone marrow cells. Instead, the result strongly suggests that the influence of host PPARalpha on tumor growth is conveyed solely by PPARalpha activity in bone marrow derived cells, because in these reciprocal transplantation experiments the PPARalpha status of the transplanted bone marrow cells recapitulates the tumor phenotype of the host. However, it cannot be excluded that the suppressor activity carried by PPARalpha-deficient bone marrow cells overrides a potential tumor stimulatory contribution of PPARalpha in other, non-bone marrow derived host cells, such as from the local stroma.
###end p 17
###begin title 18
###xml 46 50 <span type="species:ncbi:10090">Mice</span>
Depletion of Granulocytes in the PPARalpha KO Mice Restores Tumor Growth
###end title 18
###begin p 19
###xml 246 255 238 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4B</xref>
###xml 682 692 662 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000260.s002">Figure S2B</xref>
###xml 950 960 926 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000260.s002">Figure S2C</xref>
###xml 1078 1087 1050 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4C</xref>
###xml 1253 1269 1221 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4C vs. 4A</xref>
###xml 1352 1355 1320 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lin1">[2]</xref>
###xml 1357 1360 1325 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-deVisser1">[3]</xref>
###xml 1488 1497 1452 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4A</xref>
###xml 1540 1556 1500 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g004">Figure 4A and 4C</xref>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 240 244 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 1044 1048 <span type="species:ncbi:10090">mice</span>
###xml 1106 1110 <span type="species:ncbi:10090">mice</span>
###xml 1206 1210 <span type="species:ncbi:10090">mice</span>
###xml 1482 1486 <span type="species:ncbi:10090">mice</span>
Immunohistological analysis of B16-BL6 tumors in WT mice transplanted with PPARalpha-deficient bone marrow cells showed an intense increase in leukocyte staining, mimicking the intratumoral leukocyte profile of tumors grown in PPARalpha KO mice (Figure 4B). This pronounced leukocyte infiltration in WT mice transplanted with PPARalpha-deficient bone marrow cells suggests that the presence of PPARalpha within the inflammatory cells prevents an overt inflammatory response to tumors. Histological and immunohistological analysis of the dormant tumors in PPARalpha knockout mice revealed that the leukocyte population was predominantly composed of granulocytes, mainly neutrophils (Figure S2B). To corroborate an active role of these PPARalpha-deficient granulocytes in tumor suppression, we depleted them in the host animals. Flow cytometry analysis confirmed that the granulocyte-specific neutralizing antibody GR1 completely depleted neutrophils (Figure S2C). The anti-granulocyte antibody GR1 restored tumor growth rate in the PPARalpha KO mice almost completely by day 26 (Figure 4C). In PPARalpha KO mice that received the control antibody (IgG2b), tumor growth remained inhibited. Conversely, in WT mice the GR1 antibody suppressed tumor growth (Figure 4C vs. 4A), confirming the previous reports that neutrophils are necessary for tumor growth [2], [3]. However, tumor inhibition was even stronger in WT animals whose bone marrow had been replaced with that of PPARalpha KO mice (Figure 4A) as well as in PPARalpha deficient hosts (Figure 4A and 4C), again suggesting that not only is PPARalpha necessary for tumor growth, but that its absence confers a tumor suppressor activity on neutrophils.
###end p 19
###begin title 20
The Inhibitory Role of TSP-1 on Tumor Growth
###end title 20
###begin p 21
###xml 277 280 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lin1">[2]</xref>
###xml 282 286 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Coussens1">[24]</xref>
###xml 287 291 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Greten1">[26]</xref>
###xml 508 512 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Delerive1">[27]</xref>
###xml 1186 1190 1138 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Mansfield1">[28]</xref>
We next asked why are tumor growth and angiogenesis inhibited by PPARalpha-deficient leukocytes? Activated inflammatory cells promote angiogenesis, tumor cell proliferation and metastasis through the production of angiogenic mediators, growth factors, chemokines and proteases [2], [24]-[26]. A connection between the positive and negative mediators of the inflammatory response, NF-kappaB and PPARalpha, has recently been suggested, because PPARalpha has been shown to repress NF-kappaB activity/expression [27]. However, this model disagrees with our result that PPARalpha-mediated suppression of inflammation is permissive for tumor growth rather than inhibitory. Therefore, our finding suggests that PPARalpha regulates an aspect of inflammation that is different from that controlled by NF-kappaB and hence, PPARalpha modulation of inflammation affects tumor growth independently of NF-kappaB. While NF-kappaB exerts its tumor-promoting effect by induction of cytokines, we investigated whether PPARalpha deficiency suppresses tumor growth by increasing the expression of the matrix protein thrombospondin-1 (TSP-1) which inhibits angiogenesis and stimulates granulocyte migration [28].
###end p 21
###begin p 22
###xml 81 90 77 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5A</xref>
###xml 95 105 91 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0000260.s002">Figure S2D</xref>
###xml 407 416 395 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5A</xref>
###xml 471 475 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Hamano1">[29]</xref>
###xml 749 758 721 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5B</xref>
###xml 872 881 840 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5C</xref>
###xml 1051 1060 1015 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5D</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 666 670 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 961 965 <span type="species:ncbi:10090">mice</span>
In fact, TSP-1 was elevated in the plasma and tumor tissue of PPARalpha KO mice (Figure 5A and Figure S2D). Because TSP-1 can be expressed in several cell types, including tumor cells, endothelial cells and fibroblasts, we next determined the cellular origin for TSP-1 in the tumors of PPARalpha deficient mice. B16-BL6 and B16-F10/GFP melanomas in PPARalpha KO mice contained high levels of TSP-1 protein (Figure 5A), despite that these tumor cells do not express TSP-1 [29]. TSP-1 was found in tumors in PPARalpha WT mice only when the mice received bone marrow from PPARalpha KO animals. In contrast, little or no TSP-1 was detected in the tumors in PPARalpha KO mice whose bone marrow cells had been replaced by those from PPARalpha WT animals (Figure 5B). Moreover, in B16-BL6 tumors from PPARalpha KO mice treated with GR1 antibody, little or no TSP-1 was detected (Figure 5C). Purified peripheral blood leukocytes from tumor- bearing PPARalpha deficient mice expressed high levels of TSP-1 while WT leukocytes express very little if any TSP-1 (Figure 5D). Taken together, these findings suggest that in this model system, TSP-1 was produced predominantly by the inflammatory cells, and not by resident stromal cells.
###end p 22
###begin p 23
###xml 334 343 326 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5E</xref>
###xml 464 473 456 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5E</xref>
###xml 572 581 564 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5E</xref>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
To corroborate the role of TSP-1 in angiogenesis in PPARalpha deficient animals, we performed the corneal neovascularization assay in the presence of neutralizing anti-TSP-1 antibody. Suppression of vessel length (endothelial cell migration and invasion) in PPARalpha KO mice was partially reversed by inactivation of TSP-1 function (Figure 5E). There was no effect on the contiguous circumferential zone of the limbal vessel sprouting as measured by clock hours (Figure 5E). In contrast, in the WT mice, corneal neovascularization was not affected by the TSP-1 antibody (Figure 5E).
###end p 23
###begin p 24
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lawler1">[30]</xref>
###xml 324 333 320 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5F</xref>
###xml 832 841 824 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5F</xref>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 310 314 <span type="species:ncbi:10090">mice</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
###xml 818 822 <span type="species:ncbi:10090">mice</span>
Provided that neovascularization is a valid marker for tumor angiogenesis, these results are in agreement with the established role of TSP-1 in tumor inhibition [30]. However, we found that the neutralizing TSP-1 antibody did not completely restore tumor growth in PPARalpha KO mice to the level of that in WT mice, p<0.02 (Figure 5F). This may be either due to the limited access of TSP-1 antibody to the tumor bed or suggests that other endogenous inhibitors of angiogenesis may be involved. In fact, endostatin and IL-12 levels were significantly higher in PPARalpha KO mice (data not shown). Unexpectedly, we found that in WT animals neutralization of TSP-1 also had an inhibitory (rather than promoting) effect on the tumor, suppressing tumor growth by approximately 71% when compared to control antibody-treated mice, p<0.02 (Figure 5F). This suggests a complex, dualistic role of TSP-1 as a regulator of tumor growth.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 106 110 <span type="species:ncbi:10090">mice</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
In this study we identified the cellular basis for the tumor suppressing phenotype of PPARalpha deficient mice. Thus, PPARalpha pathway represents a new link between inflammation, angiogenesis, and tumorigenesis. Absence of PPARalpha in host granulocytes leads to inhibition of tumor growth, as demonstrated by: (1) transplantation of bone marrow cells from PPARalpha KO mice to PPARalpha WT mice and (2) by depletion of granulocytes by the neutralizing antibody, Gr1. Interestingly, PPARalpha deficient granulocytes carried TSP-1, a protein that inhibits angiogenesis, leukocyte migration and tumor growth. When TSP-1 was depleted by neutralizing antibody in PPARalpha KO mice, tumor growth was partially reversed.
###end p 26
###begin p 27
###xml 85 89 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Berger1">[31]</xref>
###xml 287 291 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Berger1">[31]</xref>
###xml 783 787 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Tanaka1">[32]</xref>
###xml 788 792 764 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Komuves1">[35]</xref>
###xml 937 941 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Michalik1">[14]</xref>
###xml 943 947 915 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Tordjman1">[15]</xref>
###xml 949 953 921 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Anderson1">[36]</xref>
###xml 1082 1085 1050 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Devchand1">[8]</xref>
###xml 1191 1194 1155 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Staels1">[7]</xref>
###xml 820 824 <span type="species:ncbi:10090">mice</span>
PPARalpha is best known as a critical regulator of lipid metabolism and inflammation [31], and is expressed in tissues that catabolize fatty acids such as the liver, as well as in various cell types including smooth muscle cells, monocyte/macrophages, lymphocytes, and endothelial cells [31]. PPARalpha is the molecular target of the fibrate class of lipid-lowering drugs, which have been widely used for decades in the treatment of dyslipidaemia. Upon activation by PPARalpha ligands, PPARalpha heterodimerizes with retinoic acid receptor (RXR) regulating target gene expressions. PPARalpha ligands act as PPARalpha agonists. In addition to controlling lipid levels, they also function as potent anti-inflammatory agents in diseases such as atherosclerosis, colitis, and dermatitis [32]-[35]. Accordingly, PPARalpha KO mice exhibit significant reduction of atherosclerotic lesions, delayed wound healing, and delayed liver regeneration [14], [15], [36], due to overt inflammatory processes. PPARalpha deficiency also results in a prolonged inflammatory response to lipid mediators [8]. These findings collectively suggest that PPARalpha has a physiological role in suppressing inflammation [7].
###end p 27
###begin p 28
###xml 91 95 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Peters1">[10]</xref>
###xml 97 101 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lee1">[37]</xref>
###xml 103 107 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Cattley1">[38]</xref>
###xml 450 453 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Gonzalez1">[9]</xref>
###xml 969 973 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Greten1">[26]</xref>
###xml 1238 1253 1195 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g001">Figure 1G and H</xref>
###xml 1369 1372 1318 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Gonzalez1">[9]</xref>
###xml 1794 1798 1731 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Sparmann1">[25]</xref>
###xml 84 90 <span type="species:ncbi:9606">humans</span>
###xml 195 199 <span type="species:ncbi:10090">mice</span>
###xml 726 730 <span type="species:ncbi:10090">mice</span>
PPARalpha agonists have been reported to induce liver tumors in rodents, but not in humans [10], [37], [38]. The mechanism for this species difference is still unclear. Accordingly, PPARalpha KO mice are totally resistant to liver tumors induced by PPARalpha ligands such as WY-14643 and clofibrate. This indicates that PPARalpha is required for ligand-induced peroxisome proliferation and hepatocarcinogenesis in rodents in a cell-autonomous manner [9]. It is unclear to what extent this requirement of PPARalpha for tumor growth is due to tumor cell-autonomous effects or its role in the host compartment of tumors, as shown by our current findings. In our experimental model the suppression of tumor growth in PPARalpha KO mice is mediated by leukocytes, mainly neutrophils. PPARalpha deletion is a second example for suppression of tumor growth by ablation of a gene in inflammatory cells; deletion of IKKbeta in myeloid cells inhibits epithelial cell tumor growth [26]. However, our model does not exclude a contribution by cell-autonomous tumor promoting effects of PPARalpha. In fact, we found that deletion of PPARalpha in the tumor cell itself potentiated the tumor suppressing effect of PPARalpha-deficiency in the host tissue (Figure 1G and H), in agreement with the earlier reports of the requirement for PPARalpha in PPARalpha agonist induced liver tumors [9]. Therefore, PPARalpha, in addition to NF-kappaB, may represent another example of an oncogenic protein with a dual role in cancer by controlling essential functions both in cancer cell-autonomous processes as well as processes in the tumor bed, such as inflammation and angiogenesis. Oncogenes and NF-kappaB have been shown to stimulate tumor cell proliferation and angiogenesis by modifying cytokine expression profiles [25]. Therefore, PPARalpha does not simply suppress inflammation, acting in opposition to NF-kappaB, but it does so in a qualitatively different manner in that cellular infiltrates that do not express PPARalpha, actively suppress rather than stimulate tumor growth.
###end p 28
###begin p 29
###xml 501 505 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lawler1">[30]</xref>
###xml 507 511 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Bornstein1">[39]</xref>
###xml 801 805 766 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Mansfield1">[28]</xref>
###xml 807 811 772 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-deFraipont1">[40]</xref>
###xml 813 817 778 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Short1">[41]</xref>
###xml 967 971 932 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Esemuede1">[42]</xref>
###xml 1115 1119 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Lawler2">[43]</xref>
###xml 1220 1224 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-deFraipont1">[40]</xref>
###xml 1226 1230 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Streit1">[44]</xref>
###xml 1232 1236 1194 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-WeinstatSaslow1">[45]</xref>
###xml 1364 1368 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Wang1">[46]</xref>
###xml 1456 1460 1418 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Crawford1">[47]</xref>
###xml 1461 1465 1423 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Albo1">[49]</xref>
###xml 1629 1633 1591 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Tuszynski1">[50]</xref>
###xml 1634 1638 1596 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Oshiba1">[56]</xref>
###xml 1857 1866 1819 1828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000260-g005">Figure 5C</xref>
###xml 2138 2142 2096 2100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Motegi1">[57]</xref>
###xml 2352 2356 2302 2306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Slaton1">[58]</xref>
###xml 2357 2361 2307 2311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-TjinThamSjin1">[62]</xref>
###xml 3109 3113 3055 3059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Crommelin1">[63]</xref>
###xml 1110 1114 <span type="species:ncbi:10090">mice</span>
###xml 1152 1156 <span type="species:ncbi:10090">mice</span>
###xml 1517 1522 <span type="species:ncbi:9606">human</span>
###xml 2108 2112 <span type="species:ncbi:10090">mice</span>
###xml 2380 2384 <span type="species:ncbi:10090">mice</span>
###xml 2544 2548 <span type="species:ncbi:10090">mice</span>
###xml 2899 2903 <span type="species:ncbi:10090">mice</span>
###xml 3063 3067 <span type="species:ncbi:10090">mice</span>
PPARalpha-deficient leukocytes produce TSP-1, a potent inducer of leukocyte migration and inhibitor of angiogenesis. Thrombospondin-1 (TSP-1) is a trimeric glycoprotein (450kD) that has several functional domains with different binding affinities. It binds to several cell surface receptors (CD36, integrins alphaVbeta3, alpha3beta1, alpha4beta1, alpha5beta1, heparan sulfate proteoglycans) and also binds calcium and extracellular proteins, such as plasminogen, fibrinogen, fibronectin and urokinase [30], [39]. This multitude of binding partners may explain the diversity of TSP-1 functions: TSP-1 modulates cell adhesion, migration, proliferation and differentiation regulating processes such as inhibition of angiogenesis (through CD36 and beta1- integrin) and stimulation of neutrophil migration [28], [40], [41]. TSP-1 is expressed in several cell types in the host: platelets, neutrophils, monocytes, fibroblasts, pericytes, endothelial cells, and tumor cells [42]. Through its role as an activator of TGF-beta, it also modulates inflammatory reactions which may contribute to the lethality of TSP-1 KO mice [43]. TSP-1 inhibits tumor growth in mice when overexpressed, putatively via suppression of angiogenesis [40], [44], [45]. However, TSP-1 may also act as a promoter of tumor growth, because anti-TSP-1 receptor antibody inhibited breast tumor growth [46]. Moreover, in vitro TSP-1 has been shown to promote tumor cell invasion and chemotaxis [47]-[49]. In addition, further complicating the picture, in human plasma and tumor stroma the levels of TSP-1 have been correlated with both good and poor cancer prognosis [50]-[56]. This conflicting influence of TSP-1 is recapitulated in our animal model: TSP-1 delivered by leukocytes inhibited tumor growth. However, in the WT animals neutralization of TSP-1 also strongly inhibited tumor growth (Figure 5C). A possible explanation for this apparent paradox is that TSP-1 may have a biphasic effect on angiogenesis and leukocyte migration so that low doses (as found physiologically in WT animals) stimulate and high doses (present in PPARalpha KO mice) inhibit these processes [57]. Such a "U-shape" dose-effect curve has been reported for many cytokines and bioactive molecules, such as interferon-alpha, PPARgamma ligands and endostatin which all exhibit a biphasic effect on angiogenesis [58]-[62]. Therefore, in WT mice, TSP-1 may operate in the dose-effective window of promoting inflammation which in turn stimulates angiogenesis and tumor growth. In contrast, in PPARalpha KO mice where TSP-1 is constitutively high, it would act as an inhibitor of tumor growth, perhaps through its antiangiogenic effects. Another possibility, technical rather than biological, is that the activity of TSP-1 is always inhibitory under the conditions studied, but the TSP-1 antibody itself generates the biphasic effect. High levels of TSP-1 in KO mice in the presence of TSP-1 antibodies may promote formation of large antigen - antibody complexes that facilitate TSP-1 clearance, while at low levels, as in WT mice, TSP-1 may be stabilized by the antibody [63].
###end p 29
###begin p 30
###xml 460 464 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Dave1">[64]</xref>
Given the accumulating findings pointing to the importance for tumor growth of processes in non-cancer host tissues, such as angiogenesis, inflammation and other functions mediated by residual stroma and infiltrating bone marrow cells, our results add a new element to the emerging paradigm that tumor formation is not only a cell-autonomous process. Hence, the action of genes involved in tumor formation must be seen in the broader context of host and tumor [64]. While several pro-inflammatory factors stimulate tumor growth, we report a new molecular link between inflammation and cancer, in that abnormal inflammatory processes can inhibit tumor growth and angiogenesis - thus broadening the spectrum for anticancer therapies that aim at interfering with stromal processes.
###end p 30
###begin title 31
Materials and Methods
###end title 31
###begin title 32
Tumor Xenograft Studies
###end title 32
###begin p 33
###xml 480 484 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Costet1">[65]</xref>
###xml 957 958 933 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1221 1222 1197 1198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1292 1293 1264 1265 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1350 1351 1322 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1385 1389 1357 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Panigrahy1">[59]</xref>
###xml 1595 1599 1559 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Panigrahy1">[59]</xref>
###xml 1676 1677 1640 1641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2006 2007 1966 1967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 90 98 <span type="species:ncbi:9606">Children</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 214 218 <span type="species:ncbi:10090">mice</span>
###xml 252 256 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 453 457 <span type="species:ncbi:10090">mice</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 543 551 <span type="species:ncbi:9606">Children</span>
###xml 735 740 <span type="species:ncbi:10090">mouse</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
###xml 841 845 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 1184 1188 <span type="species:ncbi:10090">mice</span>
###xml 1257 1261 <span type="species:ncbi:10090">mice</span>
###xml 1328 1333 <span type="species:ncbi:10090">mouse</span>
###xml 1337 1342 <span type="species:ncbi:10090">mouse</span>
###xml 1513 1517 <span type="species:ncbi:10090">mice</span>
###xml 1546 1551 <span type="species:ncbi:10090">mouse</span>
###xml 1555 1560 <span type="species:ncbi:10090">mouse</span>
###xml 1779 1783 <span type="species:ncbi:10090">mice</span>
###xml 1825 1829 <span type="species:ncbi:10090">mice</span>
###xml 1850 1854 <span type="species:ncbi:10090">mice</span>
###xml 2220 2225 <span type="species:ncbi:10090">mouse</span>
###xml 2369 2373 <span type="species:ncbi:10090">mice</span>
All the animal studies were reviewed and approved by the animal care and use committee of Children's Hospital Boston. Three to six-month old male PPARalpha knockout mice (129S4/SvJae), corresponding age-matched WT mice (129S1/SvIMJ, C57BL/6), obese WT mice (129S1/SvIMJ-retired breeders), C3H/HeJ and Balb/cJ mice were obtained from Jackson laboratories (Bar Harbor, ME). Retired WT breeders (35-40 gram) were used to control for weight as PPARalpha KO mice become obese with age [65]. WT mice (129S4/SvJae) were provided by Dr. John Heymach, Children's Hospital, Boston. PPARalpha WT and KO littermates were F2 generation. For tumor studies, PPARalpha negative (-/-) and PPARalpha positive (+/+) tumors were developed by transforming mouse embryonic fibroblasts (embryonic day 11) isolated from PPARalpha KO and WT mice, respectively, with SV40 large T-antigen and H-ras (generous gift from Dr. William Hahn). Tumor cells were injected subcutaneously (1x106 cells in 0.1 ml PBS). B16-BL6 melanoma cells were implanted directly from tissue culture; the growth of LLC and B16-F10/GFP tumors was achieved in 129 strains as follows: LLC and B16-F10/GFP cells were first grown in C57BL/6 mice and transplanted as pieces (1 mm3) subcutaneously into PPARalpha WT mice. When tumors were 1000-2000 mm3, they were serially passaged from mouse to mouse as 1 mm3 pieces and then grown in culture [59]. For experiments, LLC and B16-F10/GFP tumor cells were injected subcutaneously into the 129S PPARalpha WT and PPARalpha KO mice either from culture or from mouse to mouse as a cell suspension as described [59]. Tumors were measured every 3-5 days, and the volume was calculated as width2xlengthx0.52. For metastasis studies, 500,000 cells in 0.1 ml PBS were injected via tail vein (n = 15 mice/group). On day 21, when the PPARalpha WT mice died, all remaining mice were euthanized. Histological sections of livers were quantified for liver metastasis (n = 34-53 fields). For corneal tumor studies, tumor pieces (1 mm3) were implanted into the cornea, and the angiogenic response was recorded; photos were taken weekly using a slit-lamp microscope. For granulocyte depletion studies, GR-1 or control antibody (IgG2b) at 300 microg/mouse (Biolegend, San Diego, CA) was administered intraperitoneally two days prior to B16-BL6 melanoma implantation in PPARalpha WT and PPARalpha KO mice, and every 3 days post-implantation. Granulocyte depletion was confirmed by flow cytometry using phycoerythrin conjugated Ly-6G (GR-1) antibody (Biolegend, San Diego, CA).
###end p 33
###begin p 34
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
For neutralizing antibody experiments the A4.1 anti-TSP-1 monoclonal antibody (Lab Vision, Fremont, CA) (CSVTCG/CD36) or control antibody (IgM) at 50 microg/mouse were administered intraperitoneally daily to PPARalpha WT and KO mice in the corneal neovascularization and B16-BL6 melanoma experiments.
###end p 34
###begin title 35
Immunohistochemistry
###end title 35
###begin p 36
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Panigrahy1">[59]</xref>
###xml 120 123 <span type="species:ncbi:10116">rat</span>
###xml 129 134 <span type="species:ncbi:10090">mouse</span>
###xml 451 456 <span type="species:ncbi:10090">mouse</span>
###xml 632 635 <span type="species:ncbi:10116">rat</span>
###xml 641 646 <span type="species:ncbi:10090">mouse</span>
###xml 688 693 <span type="species:ncbi:10090">mouse</span>
Tumor samples were processed and immunohistochemical stainings were performed according to standard protocols [59]. For rat anti-mouse PECAM1 (BD Biosciences, San Jose, CA) staining, sections were treated with 40 microg/ml proteinase K (Roche Diagnostics Corp.) for 25 minutes at 37degreesC. Detection of PECAM1 staining was completed using the tyramide amplification system according to the manufacturer's instructions (PerkinElmer, Boston, MA). For mouse monoclonal thrombospondin-1 (clone A6.1, Lab Vision, Fremont, CA) staining, sections were pretreated with pepsin for 15 minutes at 37degreesC (Biomeda, Foster City, CA ). For rat anti-mouse CD45 (BD Biosciences, San Jose, CA), and mouse monoclonal NP57 neutrophil elastase (Lab Vision, Fremont, CA) stainings no pretreatments were needed, and stainings were performed using Innogenex IHC kit (San Ramon, CA).
###end p 36
###begin title 37
Angiogenesis Assays
###end title 37
###begin p 38
###xml 405 409 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Kenyon1">[66]</xref>
Corneal neovascularization assays were performed. Vessel length was the length of the vessels from the limbal vessel to the pellet. Vessel sprouting was measured as clock hours, the contiguous circumferential zone of the neovascularization, using a 360degrees reticule (where 30degrees of arc equals one clock hour). Vessel area was determined using the formula 0.2pixvessel lengthxclock hours of vessels [66].
###end p 38
###begin p 39
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
For in vivo Miles permeability assay, PPARalpha WT and KO mice received an intravenous injection with 0.5% Evans blue dye (100 microl) retro-orbitally. After ten minutes, the mice were given intradermal injections (50 microl) into the dorsal skin or ear at 2 different sites, consisting of vehicle control or VEGF (50 ng; R&D Systems Inc., Minneapolis, MN). Twenty minutes later the dorsal skin and/or ears were harvested for densitometric analysis to quantify dye leakage. Columns represent mean+/-standard deviation (n = 6 mice per group; experiments were performed three times).
###end p 39
###begin title 40
Transplantation of Bone Marrow Stem Cells
###end title 40
###begin p 41
###xml 178 179 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 30 34 <span type="species:ncbi:10090">mice</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 361 365 <span type="species:ncbi:10090">Mice</span>
PPARalpha WT and KO recipient mice were lethally irradiated with 14 Gy (in a split dose, 4 hours apart) 24 hours before bone marrow transplantation (BMT). Bone marrow cells (1x106) were injected retro-orbitally into recipient mice under isoflurane anesthesia. Neomycin sulfate antibiotic (2 mg/ml) was administered for two weeks post BMT in the drinking water. Mice recovered for a minimum of 2-3 months prior to tumor implantation.
###end p 41
###begin title 42
Western Blot Analysis
###end title 42
###begin p 43
###xml 960 964 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000260-Joussen1">[67]</xref>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 218 223 <span type="species:ncbi:10090">mouse</span>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
For preparation of tumor lysates from PPARalpha WT and KO mice, B16BL6 tumors were homogenized with protease inhibitor (Roche, Germany). Total protein extracts (50 microg) were analyzed on blots incubated with primary mouse monoclonal TSP-1 (Ab-11, Lab Vision, Fremont, CA) and HRP-conjugated secondary antibodies (Amersham Biosciences Corp. Piscataway, NJ). A positive control for TSP-1 was obtained from exponentially growing HUVECs. For isolation of leukocytes, peripheral blood of PPARalpha WT and KO mice was obtained by retro-orbital bleeding under isoflurane anesthesia, red cells were cleared by incubating samples for 30 minutes on ice in red blood cell lysis buffer (Sigma-Aldrich, St. Louis, MO). Leukocytes were lysed in 100 microl of a solution consisting of 20 mmol/L imidazole hydrochloride, 100 mmol/L KCl, 1 mmol/L MgCl, 1 mmol/L EGTA, 1% Triton X-100, 10 mmol/L NaF, 1 mmol/L sodium molybdenate, 1 mmol/L EDTA and protease inhibitor cocktail [67].
###end p 43
###begin title 44
TSP-1 ELISA
###end title 44
###begin p 45
###xml 124 128 <span type="species:ncbi:10090">mice</span>
TSP-1 was measured by ELISA (Cytimmune, Rockville, MD) in blood plasma collected from non-tumor bearing PPARalpha WT and KO mice. Blood was collected via retro-orbital puncture.
###end p 45
###begin title 46
Statistical Analyses
###end title 46
###begin p 47
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Statistical ananlyses were performed by Student's t test. The results were considered statistically significant for p<0.05.
###end p 47
###begin title 48
Supporting Information
###end title 48
###begin p 49
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 223 227 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 902 906 <span type="species:ncbi:10090">mice</span>
###xml 1043 1047 <span type="species:ncbi:10090">mice</span>
Tumor angiogenesis is inhibited in the cornea of PPARalpha KO mice. PPARalpha WT and KO host mice were implanted with tumor pieces (1 mm3) as indicated. (A) Comparison of PPARalpha(+/+)MEF/RS and PPARalpha(-/-)MEF/RS in WT mice day 9 and day 16. (B) PPARalpha(+/+)MEF/RS and PPARalpha(-/-)MEF/RS in PPARalpha KO day 9 and day 16. The angiogenic response of PPARalpha(-/-)MEF/RS in PPARalpha KO mice regressed by day 16. (C) Lewis Lung Carcinoma (LLC) in PPARalpha WT and KO, C3H/HeJ and Balb/cJ on day 12. LLC tumors induced tumor angiogenesis independent of host haplotype. Therefore, major histo-incompatibility (MHC) does not prevent tumor-induced neovascularization and tumor growth. In contrast, LLC tumors failed to trigger any angiogenic response in PPARalpha KO host. (D) B16-BL6 melanoma in PPARalpha WT and KO on day 16. (E) Histology of B16-BL6 melanoma in the cornea of PPARalpha WT and KO mice. Scale bars, 500 mum (left) and 100 mum (right) (F) Leukocyte (CD45, brown) staining of LLC tumors in the cornea of PPARalpha WT and KO mice. Scale bar, 100 microm.
###end p 49
###begin p 50
(8.59 MB TIF)
###end p 50
###begin p 51
Click here for additional data file.
###end p 51
###begin p 52
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 418 422 <span type="species:ncbi:10090">mice</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
(A) FACS analysis demonstrates % of CD45.1 host cells. In our bone marrow transplantation protocol, >90% of the hematopoietic system of the host was derived from the donor marrow (as proved by using CD45.1 mice as recipients and PPARalpha KO mice that are CD45.2 as donors). (B) Panleukocyte (CD45, brown) and neutrophil elastase (red) staining in PPARalpha(-/-)MEF/RS tumors in PPARalpha WT (day 25) and PPARalpha KO mice (day 55). Scale bar, 500 microm. (C) FACS analysis demonstrates granulocyte depletion in PPARalpha KO mice. (D) TSP-1 expression (brown) in B16-F10 (day 30) and PPARalpha(-/-)MEF/RS (day 60) tumors in PPARalpha KO and WT mice as determined by immunohistochemical staining. Scale bars, 100mum and 500 microm, respectively.
###end p 52
###begin p 53
(5.12 MB TIF)
###end p 53
###begin p 54
Click here for additional data file.
###end p 54
###begin p 55
Genetic Background and Transplantation Immunity.
###end p 55
###begin p 56
(0.05 MB DOC)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
We thank Deborah Freedman, Carmen Barnes, Michel Aguet, Thomas Boehm and Walter Wahli for helpful discussions in preparing the manuscript. We thank William Hahn for Large T- antigen and H-ras constructs. The excellent technical assistance of Andrea Laforme and Ricky Sanchez is acknowledged. We thank Kristin Johnson for photography.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Stromal fibroblasts in cancer initiation and progression.
###end article-title 60
###begin article-title 61
Role of infiltrated leucocytes in tumour growth and spread.
###end article-title 61
###begin article-title 62
Paradoxical roles of the immune system during cancer development.
###end article-title 62
###begin article-title 63
Immunotherapy: target the stroma to hit the tumor.
###end article-title 63
###begin article-title 64
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 64
###begin article-title 65
NF-kappaB functions as a tumour promoter in inflammation-associated cancer.
###end article-title 65
###begin article-title 66
###xml 14 19 <span type="species:ncbi:9606">human</span>
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
###end article-title 66
###begin article-title 67
The PPARalpha-leukotriene B4 pathway to inflammation control.
###end article-title 67
###begin article-title 68
The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis.
###end article-title 68
###begin article-title 69
Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643.
###end article-title 69
###begin article-title 70
Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
###end article-title 70
###begin article-title 71
###xml 83 88 <span type="species:ncbi:9606">human</span>
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma.
###end article-title 71
###begin article-title 72
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
Activators of peroxisome proliferator-activated-alpha partially inhibit mouse skin tumor promotion.
###end article-title 72
###begin article-title 73
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.
###end article-title 73
###begin article-title 74
###xml 81 85 <span type="species:ncbi:10090">mice</span>
PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.
###end article-title 74
###begin article-title 75
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.
###end article-title 75
###begin article-title 76
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.
###end article-title 76
###begin article-title 77
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice.
###end article-title 77
###begin article-title 78
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy.
###end article-title 78
###begin article-title 79
Dose-dependent response of FGF-2 for lymphangiogenesis.
###end article-title 79
###begin article-title 80
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis.
###end article-title 80
###begin article-title 81
###xml 84 95 <span type="species:ncbi:10141">guinea-pigs</span>
Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs.
###end article-title 81
###begin article-title 82
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.
###end article-title 82
###begin article-title 83
Inflammation and cancer.
###end article-title 83
###begin article-title 84
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis.
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
###end article-title 85
###begin article-title 86
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.
###end article-title 86
###begin article-title 87
###xml 38 43 <span type="species:ncbi:9606">human</span>
Thrombospondin stimulates motility of human neutrophils.
###end article-title 87
###begin article-title 88
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression.
###end article-title 88
###begin article-title 89
Tumor progression: the effects of thrombospondin-1 and -2.
###end article-title 89
###begin article-title 90
Mechanism of action of PPARs.
###end article-title 90
###begin article-title 91
###xml 147 151 <span type="species:ncbi:10116">rats</span>
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.
###end article-title 91
###begin article-title 92
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
###end article-title 92
###begin article-title 93
###xml 121 125 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atheroclerosis in LDL receptor-deficient mice.
###end article-title 93
###begin article-title 94
Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo.
###end article-title 94
###begin article-title 95
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice.
###end article-title 95
###begin article-title 96
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.
###end article-title 96
###begin article-title 97
###xml 74 80 <span type="species:ncbi:9606">humans</span>
Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
###end article-title 97
###begin article-title 98
Thrombospondins as matricellular modulators of cell function.
###end article-title 98
###begin article-title 99
Thrombospondins and tumor angiogenesis.
###end article-title 99
###begin article-title 100
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins.
###end article-title 100
###begin article-title 101
###xml 32 37 <span type="species:ncbi:9606">human</span>
The role of thrombospondin-1 in human disease.
###end article-title 101
###begin article-title 102
Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors.
###end article-title 102
###begin article-title 103
###xml 85 90 <span type="species:ncbi:9606">human</span>
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.
###end article-title 103
###begin article-title 104
###xml 58 63 <span type="species:ncbi:9606">human</span>
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.
###end article-title 104
###begin article-title 105
Inhibition of breast cancer progression by an antibody to a thrombospondin-1 receptor.
###end article-title 105
###begin article-title 106
Rapid growth of cutaneous metastases after surgical resection of thrombospondin-secreting small blue round cell tumor of childhood.
###end article-title 106
###begin article-title 107
###xml 61 66 <span type="species:ncbi:9606">human</span>
Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer.
###end article-title 107
###begin article-title 108
The effect of thrombospondin-1 and TGF-beta 1 on pancreatic cancer cell invasion.
###end article-title 108
###begin article-title 109
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Thrombospondin levels in patients with malignancy.
###end article-title 109
###begin article-title 110
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Plasma thrombospondin levels in patients with gynecologic malignancies.
###end article-title 110
###begin article-title 111
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Plasma thrombospondin levels in patients with colorectal carcinoma.
###end article-title 111
###begin article-title 112
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression.
###end article-title 112
###begin article-title 113
Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
###end article-title 113
###begin article-title 114
Independent association of angiogenesis index with outcome in prostate cancer.
###end article-title 114
###begin article-title 115
Stromal thrombospondin-1 expression is correlated with progression of esophageal squamous cell carcinomas.
###end article-title 115
###begin article-title 116
Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis.
###end article-title 116
###begin article-title 117
Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.
###end article-title 117
###begin article-title 118
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
###end article-title 118
###begin article-title 119
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
###end article-title 119
###begin article-title 120
What doesn't kill you makes you stronger. A new model for risk assessment may not only revolutionize the field of toxicology, but also have vast implications for risk assessment.
###end article-title 120
###begin article-title 121
Endostatin therapy reveals a U-shaped curve for antitumor activity.
###end article-title 121
###begin article-title 122
Immunogenicity.
###end article-title 122
###begin article-title 123
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
###end article-title 123
###begin article-title 124
Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis.
###end article-title 124
###begin article-title 125
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
A model of angiogenesis in the mouse cornea.
###end article-title 125
###begin article-title 126
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
###end article-title 126
###begin title 127
Figures and Tables
###end title 127
###begin p 128
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 767 773 <span type="species:ncbi:10090">murine</span>
###xml 794 799 <span type="species:ncbi:10090">mouse</span>
###xml 1308 1312 <span type="species:ncbi:10090">mice</span>
###xml 1385 1389 <span type="species:ncbi:10090">mice</span>
###xml 1472 1476 <span type="species:ncbi:10090">mice</span>
###xml 1561 1565 <span type="species:ncbi:10090">mice</span>
###xml 1714 1718 <span type="species:ncbi:10090">mice</span>
###xml 1829 1833 <span type="species:ncbi:10090">mice</span>
###xml 1988 1992 <span type="species:ncbi:10090">mice</span>
###xml 2154 2158 <span type="species:ncbi:10090">mice</span>
Tumor growth and metastasis are inhibited in PPARalpha knockout (KO) mice. PPARalpha wild type (WT) and PPARalpha KO mice were injected subcutaneously or intravenously with various tumor cell lines; (n) = number of mice/group. (A-C) The growth of engineered PPARalpha(+/+) MEF/RS and PPARalpha(-/-) MEF/RS tumors in PPARalpha WT and KO mice. (A) PPARalpha(+/+)MEF/RS tumor growth in PPARalpha WT (diamond gray) and KO (blacksquare, square, filled brown) mice. (B) The growth curves of PPARalpha(-/-)MEF/RS in PPARalpha WT (diamond gray) and KO (blacksquare, square, filled brown) mice.(C) Columns summarize the inhibitory effect of PPARalpha (-/-) tumor and host cells at day 30 post implantation (average+/-standard error of the mean). (D-F) The growth of different murine tumors in different mouse strains. (D) The growth of B16-BL6 melanoma was compared in WTS1 (diamond gray), WTS1/S4 (black trianglegray), KOS4 (blacksquare, square, filled brown) and KO S1/S4 (diamond pink) strains. WT S1/S4, PPARalpha WT second generation littermates from PPARalpha WT 129/S1 and KO 129/S4; KO S1/S4, PPARalpha KO second generation littermates from PPARalpha KO 129/S4. (E) Lewis lung carcinoma growth in PPARalpha WT (diamond gray), PPARalpha KO (blacksquare, square, filled brown) and C57BL/6 (black triangle blue) mice. (F) B16-F10/GFP tumor growth in PPARalpha WT, PPARalpha KO and C57BL/6 mice, blue insets demonstrate representative B16-F10/GFP tumors in PPARalpha WT and KO mice on day 30 post implantation. Scale bar, 1 cm. (G) B16-BL6 melanoma was implanted in mice of indicated genetic backgrounds. Representative B16-BL6 tumors in PPARalpha WT (diamond gray) and PPARalpha KO (blacksquare, square, filled brown) mice on day 30 post implantation are shown (blue insets). Scale bar, 1 cm. (H-I) Metastasis in PPARalpha WT and KO mice. H: Metastatic areas of B16-F10/GFP and PPARalpha(-/-)MEF/RS tumor cells at day 21 post-injection in lung and liver of PPARalpha WT (diamond gray) and KO mice (blacksquare, square, filled brown). I: Number of liver metastases in PPARalpha WT (blacksquare, square, filled gray) and KO (blacksquare, square, filled brown) mice injected with B16-F10/GFP tumor cells (average+/-standard deviation).
###end p 128
###begin p 129
###xml 456 457 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 484 488 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 672 676 <span type="species:ncbi:10090">mice</span>
###xml 684 688 <span type="species:ncbi:10090">mice</span>
Immunohistological analysis of dormant tumors in PPARalpha KO mice. The dormant tumors contain viable and proliferating cells, and show decreased microvessel (PECAM1) and increased leukocyte (CD45) staining. (A) Dormant PPARalpha(-/-)MEF/RS tumors in PPARalpha KO mice from day 60 post-tumor implantation revealed abundant SV40 large T-antigen staining and proliferation (Ki-67). Dormant PPARalpha(-/-)MEF/RS tumors on day 60 were implanted as pieces (1 mm3) into PPARalpha WT and KO mice (3 mice in each group). (B) Immunohistochemical analysis of subcutaneous B16-F10/GFP tumors (H&E, CD45/brown color, PECAM-1/brown color) from day 30 post-implantation in PPARalpha WT mice and KO mice. Scale bars, 100 microm.
###end p 129
###begin p 130
###xml 109 113 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 260 266 <span type="species:ncbi:10090">murine</span>
###xml 326 331 <span type="species:ncbi:10090">mouse</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 518 522 <span type="species:ncbi:10090">mice</span>
###xml 695 699 <span type="species:ncbi:10090">mice</span>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
FGF2-induced corneal neovascularization and VEGF-induced vascular permeability are inhibited in PPARalpha KO mice. (A) FGF-2 (20 ng) stimulates corneal neovascularization in WT 129S4/SvJae strain, WT 129S1/SvIMJ strain and obese WT (129S1/SvJae) mice. Soluble murine VEGFR1 completely inhibits FGF2-induced angiogenesis in WT mouse (sVEGFR1). FGF2-induced corneal neovascularization is potently suppressed in PPARalpha KO mouse (KOS4). Vessel length, clock hours, and area of neovascularization in PPARalpha WT and KO mice are represented in bar graphs (average+/-standard deviation). (B) Evans blue dye leakage in dorsal skin and ears after injection with VEGF or saline in PPARalpha WT and KO mice (n = 6 mice/group). Spectrophotometric analysis of extravasated Evans blue of skin and ear is represented in bar graph (average+/-standard deviation).
###end p 130
###begin p 131
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 764 768 <span type="species:ncbi:10090">mice</span>
The inhibitory effect of PPARalpha resides in the hematopoietic compartment. (A) B16-BL6 melanoma growth in WT mice receiving KO bone marrow (KO BM -->WT mice) compared to PPARalpha KO mice receiving WT bone marrow (WT BM -->KO mice). WT bone marrow "rescues" tumor growth in PPARalpha KO mice. (B) Subcutaneous B16-BL6 tumors on day 28 post-implantation show abundant CD45 staining in PPARalpha WT mice receiving KO bone marrow (KO -->WT). In B16-BL6 tumors in KO mice receiving WT bone marrow (WT-->KO) CD45 staining (shown in green) was markedly reduced. Hoechst staining of nuclei is blue. Scale bar, 100 microM. (C) Effect of granulocyte depletion using Gr-1 antibody or control antibody (Ctr Ab, IgG2b) on B16-BL6 melanoma growth rate in PPARalpha KO and WT mice.
###end p 131
###begin p 132
###xml 178 182 <span type="species:ncbi:10090">mice</span>
###xml 304 308 <span type="species:ncbi:10090">mice</span>
###xml 461 465 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
###xml 692 696 <span type="species:ncbi:10090">mice</span>
###xml 888 892 <span type="species:ncbi:10090">mice</span>
###xml 1222 1226 <span type="species:ncbi:10090">mice</span>
Effects of thrombospondin-1 (TSP-1) on angiogenesis and tumor growth in the PPARalpha-deficient state. (A) First panel demonstrates TSP-1 levels in plasma of PPARalpha KO and WT mice (ELISA); second panel shows TSP-1 levels in B16-BL6 and B16-F10/GFP tumor lysates at day 30 grown in PPARalpha WT and KO mice (western blotting); positive CTR for TSP-1, proliferating HUVECs. (B) Western blot analysis of TSP-1 protein in B16-BL6 tumor lysates from PPARalpha KO mice receiving WT bone marrow (WT BM-->KO), and PPARalpha WT mice receiving KO bone marrow (KO BM-->WT); positive CTR for TSP-1, proliferating HUVECs. (C) TSP-1 protein expression is lost in B16-BL6 tumor lysates from PPARalpha KO mice depleted of granulocytes (GR-1 antibody); positive CTR for TSP-1, proliferating HUVECs. (D) Western blot analysis of TSP-1 expression from isolated leukocytes from tumor-bearing PPARalpha KO mice; positive CTR, proliferating HUVECs. Levels of beta-actin demonstrate protein loading. (E) Effect of TSP-1 neutralizing antibody and control antibody (IgM) on vessel length (n = 6-9 eyes), clock hours (n = 5-9 eyes) and vessel area (n = 5-9 eyes) in the corneal neovascularization assay. (F) B16-BL6 melanoma growth in KO and WT mice treated with TSP-1 neutralizing or control antibody (IgM).
###end p 132
###begin p 133
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 133
###begin p 134
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by the Stop & Shop Pediatric Brain Tumor Fund and the C.J. Buckley Pediatric Brain Tumor Research Fund (M.K.) and Department of Defense Innovator Award #W81XWH-04-1-0316 and private philanthropic funds (J.F.).
###end p 134

